Related Experiment Video
Updated: Feb 3, 2026
Models and Methods to Evaluate Transport of Drug Delivery Systems Across Cellular Barriers
Published on: October 17, 2013
Reconstituted HDL: Drug Delivery Platform for Overcoming Biological Barriers to Cancer Therapy
Sangram Raut1, Linda Mooberry1, Nirupama Sabnis1
1Lipoprotein Drug Delivery Research Laboratory, Department of Physiology and Anatomy, University of North Texas Health Science Center, Fort Worth, TX, United States.
Abstract:
Drug delivery to malignant tumors is limited by several factors, including off-target toxicities and suboptimal benefits to cancer patient. Major research efforts have been directed toward developing novel technologies involving nanoparticles (NPs) to overcome these challenges. Major obstacles, however, including, opsonization, transport across cancer cell membranes, multidrug-resistant proteins, and endosomal sequestration of the therapeutic agent continue to limit the efficiency of cancer chemotherapy. Lipoprotein-based drug delivery technology, "nature's drug delivery system," while exhibits highly desirable characteristics, it still needs substantial investment from private/government stakeholders to promote its eventual advance to the bedside. Consequently, this review focuses specifically on the synthetic (reconstituted) high-density lipoprotein rHDL NPs, evaluating their potential to overcome specific biological barriers and the challenges of translation toward clinical utilization and commercialization. This highly robust drug transport system provides site-specific, tumor-selective delivery of anti-cancer agents while reducing harmful off-target effects. Utilizing rHDL NPs for anti-cancer therapeutics and tumor imaging revolutionizes the future strategy for the management of a broad range of cancers and other diseases.
Insights
Synthetic high-density lipoprotein nanoparticles (rHDL NPs) offer a promising solution for targeted cancer drug delivery. These nanoparticles overcome biological barriers, enhancing therapeutic efficacy and reducing side effects for improved patient outcomes.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Cancer chemotherapy faces challenges like off-target toxicity and limited efficacy.
- Nanoparticles (NPs) are explored to improve drug delivery, but face obstacles like opsonization and endosomal sequestration.
- Lipoprotein-based systems show promise but require further development for clinical use.
Purpose of the Study:
- To review synthetic (reconstituted) high-density lipoprotein nanoparticles (rHDL NPs) for cancer drug delivery.
- To evaluate the potential of rHDL NPs in overcoming biological barriers in cancer treatment.
- To assess the challenges and opportunities for clinical translation and commercialization of rHDL NPs.
Main Methods:
- Review of existing literature on rHDL NPs for drug delivery.
- Analysis of rHDL NP properties in overcoming cancer-related biological barriers.
- Evaluation of clinical translation and commercialization hurdles for rHDL NP technology.
Main Results:
- rHDL NPs demonstrate potential for site-specific, tumor-selective delivery of anti-cancer agents.
- This approach can significantly reduce harmful off-target toxicities associated with chemotherapy.
- rHDL NPs offer a robust drug transport system with broad applicability in cancer management.
Conclusions:
- rHDL NPs represent a revolutionary approach for anti-cancer therapeutics and tumor imaging.
- Further investment is crucial to advance rHDL NP technology from research to clinical application.
- Utilizing rHDL NPs can transform cancer treatment strategies and improve patient care.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:28Drug Therapy
Antianxiety Medications
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:19Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
01:16Drug Delivery: Overview
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
01:23Factors Affecting Drug Distribution: Physiological Barriers
The capillary endothelial barrier allows only smaller molecules below 600 Da (Daltons) to pass through. It also restricts drugs like heparin that are bound to blood components, limiting their movement within the bloodstream.
The...